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ABSTRACT 24 
Lysosomal acid lipase (LAL) is responsible for the hydrolysis of cholesteryl esters (CE) and 25 
triglycerides (TG) within the lysosomes; generated cholesterol and free fatty acids (FFA) are 26 
released in the cytosol where they can regulate their own synthesis and metabolism. When 27 
LAL is not active, as in case of genetic mutations, CE and TG accumulate in the lysosomal 28 
compartment, while the lack of release of cholesterol and FFA in the cytosol leads to an 29 
upregulation of their synthesis. Thus, LAL plays a central role in the intracellular homeostasis 30 
of lipids. Since there are no indications about the effect of different lipid-lowering agents on 31 
LAL activity, aim of the study was to address the relationship between LAL activity and the 32 
type of lipid-lowering therapy in a cohort of dyslipidemic patients. 33 
LAL activity was measured on dried blood spot from 120 patients with hypercholesterolemia 34 
or mixed dyslipidemia and was negatively correlated to LDL-cholesterol levels. Among 35 
enrolled patients, ninety-one were taking one or more lipid-lowering drugs, as statins, fibrates, 36 
ezetimibe and omega-3 polyunsaturated fatty acids. When patients were stratified according 37 
to the type of lipid-lowering treatment, i.e. untreated, taking statins or taking fibrates, LAL 38 
activity was significantly higher in those with fibrates, even after adjustment for sex, age, BMI, 39 
lipid parameters, liver function, metabolic syndrome, diabetes and statin use. In a subset of 40 
patients tested after 3 months of treatment with micronized fenofibrate, LAL activity raised by 41 
21%; the increase was negatively correlated with baseline LAL activity. 42 
Thus, the use of fibrates is independently associated with higher LAL activity in dyslipidemic 43 
patients, suggesting that the positive effects of PPAR-α activation on cellular and systemic 44 
lipid homeostasis can also include an improved LAL activity. 45 
Keywords: Lysosomal acid lipase, fibrates, statins, dyslipidemia. 46 
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1. Introduction 48 
Lysosomal acid lipase (LAL) is coded by the LIPA gene on chromosome 10 and it is 49 
responsible for the hydrolysis of cholesteryl esters (CE) and triglycerides (TG) within the 50 
lysosomes [1]. Generally, these lipids have been internalized by the receptor-mediated 51 
endocytosis of apoB-containing lipoproteins, but can also derive from intracellular lipid 52 
droplets through the activation of the autophagic process [2]. The reaction catalyzed by LAL 53 
generates unesterified cholesterol (UC) and free fatty acids (FFA), which are released into the 54 
cytosol where they can regulate their own synthesis and metabolism [1]. When LAL is not 55 
active, as in case of mutations in the LIPA gene affecting protein synthesis or function, CE 56 
and TG accumulate in the lysosomal compartment in the peculiar form of microvesicles, 57 
especially in the liver and in macrophages throughout the body. Mutations in the LIPA gene 58 
cause two recessive diseases depending on residual LAL activity, namely Wolman Disease 59 
(WD) and Cholesteryl Ester Storage Disease (CESD) [3]. WD is the neonatal-onset and 60 
fulminant type, while CESD can be diagnosed in childhood or adulthood. Clinically, CESD 61 
patients present with hepatomegaly, splenomegaly, malabsorption and increased 62 
cardiovascular risk [4]. Biochemically, hypercholesterolemia (variably associated with 63 
hypertriglyceridemia) and low plasma levels of HDL-cholesterol have been described, 64 
together with elevation of liver enzymes [4]. The alteration of the lipid profile is the 65 
consequence of the lack of release of UC and FFA in the cytosol of LAL-deficient 66 
hepatocytes; indeed, the activation of the sterol regulatory element-binding proteins 67 
(SREBPs) leads to an upregulation of cholesterol and FFA synthesis and of VLDL secretion. 68 
In addition, the lower generation of oxysterols from UC in the cytosol results in an impaired 69 
activation of liver X receptors (LXRs), with a consequent reduction of ABCA1 expression and 70 
HDL biogenesis [5]. Thus, the impaired intracellular lipid metabolism in LAL-deficient cells can 71 
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affect circulating lipid levels. However, while single nucleotide polymorphisms within the LIPA 72 
gene were associated with the risk of coronary artery disease [6], it is not clear whether LAL 73 
activity is associated with plasma lipid levels in the general population. 74 
Besides the recent availability of recombinant LAL for enzyme replacement therapy, CESD 75 
patients are usually given statins to manage the hypercholesterolemia, while low HDL-76 
cholesterol and hypertriglyceridemia could suggest the use of fibrates [7,8]. These molecules 77 
can modulate plasma lipid levels by rewiring cellular lipid metabolism; however, their direct 78 
effect on LAL activity has not been addressed to date. Thus, aim of the present study was to 79 
investigate the relationship between LAL activity, biochemical/anthropometric variables and 80 
the type of lipid-modifying therapy in a cohort of dyslipidemic patients.  81 
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2. Methods 82 
2.1 Patients 83 
Patients with hypercholesterolemia or mixed dyslipidemia were enrolled among those 84 
attending the Lipid Clinics at the Niguarda, Policlinico and Bassini Hospitals, as part of a 85 
study aimed at the identification of candidates for genetic LAL deficiency. Patients were 86 
selected on the base of the following criteria: (i) total cholesterol ≥ 250 mg/dl or LDL-87 
cholesterol ≥ 160 mg/dl without lipid-lowering therapy, (ii) body mass index (BMI) ≤ 28 kg/m2 88 
[9]. The study conformed to the guidelines set out in the Declaration of Helsinki and was 89 
approved by the pertinent IRBs; all enrolled patients gave written informed consent for 90 
participation in the study. None of the enrolled patients was affected by genetic LAL 91 
deficiency. The database was retrospectively analyzed to assess the relationship between 92 
LAL activity and biochemical/clinical features at enrollment. 93 
 94 
2.2 Clinical evaluation 95 
Body mass index (BMI), waist circumference (WC), concomitant diseases and medications 96 
were recorded at the time of LAL evaluation. The presence of hepatomegaly was assessed 97 
by liver examination and/or on the base of abdominal imaging (abdominal ultrasound, 98 
computerized tomography or magnetic resonance), revealing fatty liver appearance or 99 
hepatomegaly. Fatty liver index (FLI) was calculated as described [10]. In all subjects, daily 100 
alcohol intake was lower than 20 g in females and 30 g in males (confirmed by at least one 101 
family member). 102 
 103 
2.3 Biochemical analyses 104 
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Blood samples were collected in EDTA tubes after an overnight fast. Dried blood spot cards 105 
(DBS, GE Healthcare Whatman 903) were immediately prepared, dried overnight at room 106 
temperature and stored at -20°C until assayed for LAL activity. Plasma samples were 107 
obtained by low-speed centrifugation and stored at 4°C. 108 
Plasma levels of liver enzymes, total and HDL cholesterol, triglycerides and glucose were 109 
determined by enzymatic techniques on a Roche c311 automatic analyzer (Roche 110 
Diagnostics). LDL-cholesterol was calculated by the Friedewald’s formula. 111 
LAL activity on DBS was measured by fluorescence using 4-methylumbelliferone palmitate (4-112 
MUP, Cayman Chemicals), cardiolipin (Avanti Polar Lipids) and the selective LAL inhibitor 113 
Lalistat 2 (Sigma Aldrich), according to the method of Hamilton et al. [11]. Briefly, a 3.2 mm 114 
spot was punched from DBS card and eluted in 200 µl H2O for 1h at room temperature. Forty 115 
µl of eluted sample were incubated with H2O or with 30 µM Lalistat-2 for 10 minutes at 37°C 116 
and then with 150 µl of 0.15 M acetate buffer pH 4.0, 1% Triton X-100 containing cardiolipin 117 
and 4-MUP for 3h at 37°C. Assay was performed in 96-well black plates. The generation of 118 
fluorescent 4-methylumbelliferone (4-MU) was detected by the Synergy H1 Multi-Mode 119 
microplate reader and GEN5 software (BioTek); excitation was set at 320nm and emission at 120 
460nm. A standard curve of 0–2.5 nmol 4-MU (Sigma Aldrich) was built. LAL activity was 121 
calculated by subtracting the activity in the inhibited reaction (with Lalistat 2) from uninhibited 122 
reaction (with H2O) and expressed as nmol of generated 4-MU/spot/h. The coefficient of 123 
variation of the assay is 8.5%. Normal values of LAL activity are >0.80 nmol/spot/h. DBS 124 
cards were tested for quality by measuring beta-galactosidase activity as described [12]; new 125 
DBS cards were prepared if beta-galactosidase activity was below 90 pmol/spot/h [12]. 126 
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In a subgroup of 11 patients taking no medications and with clinical indication for fibrates after 127 
dietary intervention (i.e. plasma levels of triglycerides above 200 mg/dl), DBS cards were 128 
collected before and after 3 months of treatment with micronized fenofibrate 145 mg/day. 129 
 130 
2.4 Statistical analysis 131 
Continuous variables are expressed as mean±SD, and categorical variables as cases and 132 
percentages, if not otherwise stated. Homogeneity of variance was assessed using a 133 
Levene’s test and normal distribution was tested by Shapiro-Wilk test. Non-normally 134 
distributed variables were log-transformed before proceeding to the analysis. Comparisons 135 
between groups of treatment were assessed by one-way ANOVA for independent samples. 136 
When variables were still non-normally distributed after log-transformation, a Kruskal-Wallis 137 
test was performed. Differences in LAL activity between treatment groups were assessed by 138 
covariance analysis (ANCOVA) and adjusted for age, sex, BMI, total cholesterol, triglycerides, 139 
LDL-cholesterol, HDL-cholesterol, presence of hepatomegaly, concomitant diseases and 140 
medications. A Spearman's rank-order correlation was run to assess the relationship between 141 
LAL activity and all other variables. Differences between pre- and post-treatment with 142 
micronized fenofibrate were assessed by paired t-test or Wilcoxon signed-rank test for 143 
normally and non-normally distributed variables, respectively. Pearson’s product-moment 144 
correlation was used to assess the relation between percent change and baseline LAL 145 
activity. All tests were 2-sided and P values < 0.05 were considered as statistically significant. 146 
Statistical analysis was performed by using SPSS version 25.0 software (SPSS Inc., Chicago, 147 
USA).  148 
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3. Results 149 
3.1 Features of enrolled patients 150 
Dyslipidemic patients were mainly males and average BMI was within the normal range 151 
(Table 1). Overall, they displayed a moderate mixed dyslipidemia, with elevation of both total 152 
cholesterol and triglyceride levels (Table 1). Fasting glucose, liver function and LAL activity 153 
were in the normal range (Table 1). Eight subjects (6.7%) were in secondary prevention, 10 154 
(8.3%) were diabetics and 36 (30%) were hypertensive. Nineteen patients (15.8%) had 155 
metabolic syndrome according to the NCEP/ATPIII criteria [13]. LAL activity was negatively 156 
correlated with LDL-cholesterol levels (rs(115)=-0.217, P=0.020). No other correlations were 157 
found between LAL activity and the biochemical/anthropometric variables listed in table 1. 158 
Ninety-one patients (75.8%) were taking one or more lipid-lowering drugs on a stable 159 
treatment regimen for at least 4 weeks (Table 1). Among the 57 patients treated with statins, 160 
only 6 were given a high-intensity one. Thirty patients were taking statins alone, 13 statins 161 
plus ezetimibe (2 with fenofibrate and 3 with 1 g/die omega-3 polyunsaturated fatty acids - 162 
PUFAs), 7 statins plus 1 g/die omega-3 PUFAs and 7 statins plus fibrates (1 with omega-3 163 
PUFAs). Among the 36 patients treated with fibrates, 21 were given fenofibrate 145 mg, 8 164 
bezafibrate 400 mg and 7 gemfibrozil 600-900 mg. Eighteen were given fibrates alone, 8 165 
fibrates plus 1-3 g/die omega-3 PUFAs and 1 fibrates plus ezetimibe. Seven patients were 166 
treated with 1-3 g/die omega-3 PUFAs alone. 167 
Patients were then divided according to the type of lipid-lowering treatment as indicated in 168 
table 2 and mean LAL activity was calculated for each group. Due to similar mean LAL levels, 169 
three main treatment categories were identified: patients untreated or taking only omega-3 170 
PUFAs (category 1), patients taking statins with or without ezetimibe or omega-3 PUFAs 171 
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(category 2) and patients taking fibrates with or without statins or omega-3 PUFAs (category 172 
3). 173 
3.2 Relationship between LAL activity and treatment category 174 
Features of patients belonging to the 3 different treatment categories are reported in table 1. 175 
Patients were comparable for sex distribution, WC, total cholesterol, and liver function. 176 
Dyslipidemic patients taking statins displayed lower BMI and TG values, and higher HDL-177 
cholesterol if compared to the other two groups. Fasting glucose was slightly increased in the 178 
fibrate group. Patients taking no medications were younger and their plasma levels of LDL-179 
cholesterol were higher (Table 1). While the prevalence of hypertension and cardiovascular 180 
events were comparable between the 3 categories, a higher rate of metabolic syndrome and 181 
diabetes where found among fibrate-treated patients compared to the other groups (19% and 182 
64% respectively, vs 7% and 6% in statin-treated group, and 6% and 0% in the untreated 183 
group, P<0.001 for metabolic syndrome and P=0.003 for diabetes). 184 
Interestingly, LAL activity was significantly different between the 3 groups, with patients taking 185 
fibrates showing the highest activity (Table 1 and Figure 1). LAL activity was significantly 186 
different between the treatment groups also when adjusted for sex, age, BMI, total 187 
cholesterol, triglycerides, LDL-cholesterol, HDL-cholesterol presence of hepatomegaly, 188 
presence of metabolic syndrome or diabetes and statin use (Table 1). 189 
 190 
3.3 Effect of fibrates on LAL activity 191 
To further address the effects of fibrate treatment on LAL activity, a pilot study was 192 
performed. Eleven male patients (mean age 43.3±8.7 years) were selected among those 193 
taking no medications and with TG values above 200 mg/dl after dietary intervention. They 194 
were given 145 mg of micronized fenofibrate for 3 months without other concomitant lifestyle 195 
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changes. After treatment, patients showed no changes of BMI, LDL-cholesterol and 196 
transaminases. Although with great variability, total cholesterol and TG were reduced by 8.7% 197 
and 32.1%, respectively, while HDL-cholesterol increased by 18.9% (Table 3). Fatty liver 198 
index also tended to decrease. DBS were collected before and after treatment with fenofibrate 199 
for LAL activity assay. Even in this small number of patients, a significant 20.8% increase of 200 
LAL was observed after fenofibrate (P<0.001, Figure 2). Interestingly, LAL increased in 10 201 
patients (range 6.7-51.3%), while was almost unchanged in 1 patient (+0.7%). Furthermore, 202 
the extent of LAL increase was inversely related to baseline LAL (r=-0.664, P=0.026, Figure 203 
2).  204 
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4. Discussion 205 
LAL activity was evaluated in a cohort of dyslipidemic patients with a low incidence of other 206 
metabolic alterations; indeed, body weight, blood glucose and parameters of liver function 207 
were in the normal range. The first finding of the study is the negative correlation between 208 
LAL activity and plasma LDL-cholesterol in absence of a genetic defect, suggesting that 209 
intracellular LAL may play a role in the modulation of systemic cholesterol levels even in the 210 
normal range of activity. Consistently, several genome wide association studies found an 211 
association between single nucleotide polymorphisms in the LIPA gene and the incidence of 212 
coronary artery disease, although the impact of such variants on LAL expression and activity 213 
is still debated [6,14-17]. The second aim of the study was to investigate the effect of lipid-214 
lowering drugs on LAL activity, which was unaddressed to date. We showed for the first time 215 
that the treatment with fibrates is associated with higher LAL values in dyslipidemic patients, 216 
while omega-3 PUFAs and statins showed no effect. The association was significant even 217 
after adjustment for several anthropometric, clinical and biochemical parameters. In a recent 218 
paper, Baratta et al. showed that statin use was less frequent in NAFLD patients having a 219 
LAL activity below the median of their cohort [18]. We did not observed a significant effect of 220 
statin treatment on LAL activity, but this discrepancy could be due to the striking differences 221 
between the patients enrolled in the two studies. Indeed, Baratta et al. analyzed obese 222 
patients (mean BMI was 30.5 mg/k2) with fatty liver and higher incidence of metabolic 223 
syndrome (70.5%) if compared to our patients. 224 
To further investigate the effect of fibrates on LAL activity, a pilot study was performed. 225 
Eleven patients with clinical indication for fibrates were given micronized fenofibrate for 3 226 
months and LAL activity was measured before and after treatment. Standing all the limitations 227 
of this small and uncontrolled study, we were able to show for the first time that LAL activity 228 
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significantly improved after fenofibrate and that the lower was baseline LAL the higher was 229 
the improvement mediated by fenofibrate. In addition, although far from statistical 230 
significance, a tendency towards a reduction of fatty liver index was also detected after 231 
fenofibrate. These findings suggest that the activation of PPAR-α receptors by fibrates could 232 
rewire intracellular lipid metabolism also leading to an increase of LAL activity and are worth 233 
of a confirmation in larger and controlled studies with novel and more potent PPARα agonists, 234 
as elafibranor or pemafibrate [19,20]. 235 
As stated above, the relevance of our study is limited by the small sample size of both the 236 
retrospective and intervention studies, and by the uncontrolled design of the pilot study with 237 
fenofibrate. However, it provides additional evidence on the usefulness of fibrates in the 238 
management of dyslipidemias. Atherogenic dyslipidemia, characterized by small dense LDL, 239 
elevated triglycerides and reduced HDL-cholesterol [21], which can benefit from fibrates, is 240 
frequently associated with insulin resistance and with other features of the metabolic 241 
syndrome; fibrates were shown to improve glycemic control in these patients [22]. Our results 242 
suggest a potential additional effect of fibrates through the improvement of LAL activity, 243 
especially when it is impaired (as in patients with fatty liver, a common feature of the 244 
metabolic syndrome [18]). 245 
Dedicated studies are needed to address the mechanisms responsible for LAL increase after 246 
PPARα activation. However, based on the known effects of PPARα agonists, some 247 
speculations are possible. First, PPARα agonists could increase LAL expression through the 248 
activation of transcription factor EB (TFEB). TFEB is the master regulator of lysosomal 249 
biogenesis and, consequently, of LAL expression. Recently, peroxisome proliferator 250 
responsive elements were identified in the promoter region of TFEB and it has been shown 251 
that PPARα, together with PPAR gamma coactivator 1α and retinoid X receptors, can 252 
13 
 
promote the transcriptional activation of TFEB [23]. In addition, PPARα agonists could directly 253 
promote LAL activity through their modulation of intracellular lipid metabolism. Unesterified 254 
cholesterol and free fatty acids are the product of the LAL reaction in the lysosomes; while UC 255 
is actively transported in the cytosol by the Niemann-Pick disease type C1 protein, FFA likely 256 
diffuse between the two compartments according to the concentration gradient [24]. Since 257 
PPARα activation increase the catabolism of intracellular FFA through the stimulation of the 258 
β-oxidation [25], it could improve LAL activity by promoting the flux of generated FFA to the 259 
cytosol. 260 
In conclusion, the activation of the PPARα receptors could positively affect systemic lipid 261 
homeostasis also by increasing LAL activity, through the stimulation of intracellular catabolism 262 
of lipoproteins and lipid droplets.  263 
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Table 1. Characteristics of patients divided according to treatment category 
 All patients Category 1 Category 2 Category 3 P values 
Main treatment  None Statins Fibrates  
N 120 36 48 36 - 
Age, y 57.8 ±13.8 50.3±14.3 61.2±13.4 60.8±10.7 0.001 
Sex, m/f 90/30 28/8 33/15 29/7 0.419 
BMI, kg/m2 25.6±2.9 25.8±2.3 24.8±3.0 26.5±3.1 0.015 
WC, cm 96.3±6.6 94.4±6.3 96.6±7.0 97.9±6.2 0.165 
Total cholesterol, mg/dl 226.1±46.2 238.8±40.3 216.5±43.6 226.3±52.6 0.053 
Triglycerides, mg/dl 196.2±129.6 214.9±136.0 157.7±62.7 227.8±171.4 0.025 
LDL-cholesterol, mg/dl 140.7±41.7 156.1±41.8 134.2±44.2 134.3±34.7 0.040 
HDL-cholesterol, mg/dl 47.3±12.9 42.9±12.6 52.1±11.1 45.1±13.5 0.002 
Fasting glucose, mg/dl 93.1±27.2 86.5±10.1 86.6±14.8 107.4±41.5 0.001 
AST, U/l 25.0±7.4 25.6±8.1 23.1±6.4 27.1±7.4 0.042 
ALT, U/l 30.4±15.2 34.5±18.8 26.0±10.1 32.6±16.2 0.086 
Gamma-GT, U/l 38.5±43.4 49.8±65.0 33.0±35.2 36.4±28.2 0.650 
Hepatomegaly, n (%) 40 (34.0) 11 (32.3) 12 (25) 17 (47.2) 0.101 
Fatty liver index 46.9±26.9 56.2±24.0 48.2±19.1 59.1±19.1 0.093 
LAL activity, nmol/spot/h 1.21±0.42 1.09±0.40 1.17±0.31 1.37±0.53 0.018 
Adjusted LAL activity, 
nmol/spot/h n.a. 
1.03 (0.80-
1.25) 
1.23 (1.01-
1.45) 
1.37 (1.20-
1.55) 0.019 
Data are mean±SD or as number (percentage) of cases. Adjusted LAL activity is expressed 
as means (95% CI). Differences between treatment categories were tested by one-way 
ANOVA or Kruskal-Wallis, where appropriate. For categorical variables, Pearson’s Chi-square 
test was used. In the adjusted model, LAL activity was adjusted for age, sex, BMI, total 
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cholesterol, triglycerides, LDL-cholesterol, HDL-cholesterol, glucose, hepatomegaly, statin 
use, metabolic syndrome and diabetes. 
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Table 2. LAL activity according to lipid-lowering treatment 
Treatment type n LAL activity (nmol/spot/h) Treatment category P-value 
None 29 1.09±0.42 1  
Omega-3 PUFAs 7 1.06±0.37 1 0.874* 
Statins 30 1.20±0.33 2  
Statins+ezetimibe 11 1.14±0.30 2  
Statins+omega-3 PUFAs 7 1.12±0.31 2 0.573# 
Fibrates 19 1.42±0.50 3  
Fibrates+statins 9 1.43±0.66 3  
Fibrates+omega-3 PUFAs 8 1.30±0.61 3 0.691# 
Data are expressed as mean±SD. P-values were calculated by one-way ANOVA for 
treatment category 1 (*) and by Kruskal-Wallis test for treatment category 2 and 3 (#).  
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Table 3. Biochemical and anthropometric parameters before and after treatment with 
fenofibrate 
 Before After P values 
BMI, kg/m2 27.3±2.5 27.5±2.5 0.945 
Total cholesterol, mg/dl 238.9±41.3 218.0±51.8 0.077 
Triglycerides, mg/dl 294.1±138.8 199.7±118.3 0.111 
LDL-cholesterol, mg/dl 146.0±49.7 130.1±42.6 0.171 
HDL-cholesterol, mg/dl 40.2±10.7 47.8±18.8 0.073 
AST, U/l 26.3±13.4 31.3±10.8 0.174 
ALT, U/l 33.9±24.4 44.8±21.3 0.164 
Gamma-GT, U/l 34.7±17.6 39.2±32.2 1.000 
Fatty liver index 69.7±17.7 62.0±20.7 0.093 
LAL activity, nmol/spot/h 1.03±0.31 1.24±0.30 <0.001 
Data are expressed as mean±SD. Differences between before and after treatment with 
micronized fenofibrate were assessed by Wilcoxon signed-rank test or Wilcoxon-rank, where 
appropriate.  
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FIGURE LEGENDS 
 
Fig. 1. LAL activity in dyslipidemic patients according to treatment category. 
LAL activity was measured on DBS. Boxes indicate the median and 25th-75th percentiles, 
capped bars the 10th-90th percentiles. None: patients untreated or given omega-3 PUFAs, 
n=36. Statins: patients taking statins alone or in combination with ezetimibe/omega-3 PUFAs, 
n=48. Fibrates: patients taking fibrates alone or in combinations with statins/omega-3 PUFAs, 
n=36. 
 
Fig. 2. LAL activity before and after treatment with fenofibrate 
Panel A, LAL activity was measured on DBS from 11 patients before and after 3 months 
treatment with 145 mg micronized fenofibrate. Panel B, correlation between baseline LAL 
values and percent change after treatment. 
